Protara Therapeutics
TARA
27 hedge funds and large institutions have $20.2M invested in Protara Therapeutics in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
875% more capital inflows, than outflows
Capital inflows: $3.79M | Capital outflows: $389K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
8.19% more ownership
Funds ownership: 50.68% → 58.86% (+8.2%)
8% more funds holding
Funds holding: 25 → 27 (+2)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
New Leaf Venture Partners
New York
|
+$3.46M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$152K |
| 3 |
Renaissance Technologies
New York
|
+$69K |
| 4 |
Boothbay Fund Management
New York
|
+$60.5K |
| 5 |
Virtu Financial
New York
|
+$32.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
-$216K |
| 2 |
DRW Securities
Chicago,
Illinois
|
-$113K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$45K |
| 4 |
Panagora Asset Management
Boston,
Massachusetts
|
-$10.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5K |
TARA Hedge Fund Activity: Q3 2018 in Review
27 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2018, worth a combined $20.2M — down 7.3% from $21.9M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TARA positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was New Leaf Venture Partners, opening a new position worth an estimated $3.46M. The largest seller was Perceptive Advisors, cutting an estimated $216K.
- 27 institutional investors held Protara Therapeutics (TARA) as of Q3 2018, up from 25 in Q2 2018.
- Funds reported $20.2M of Protara Therapeutics stock for Q3 2018, down 7.3% quarter-over-quarter.
- 4 funds opened new Protara Therapeutics positions in Q3 2018 and 2 closed out, a net change of +2 holders.
- The largest Protara Therapeutics buyer in Q3 2018 was New Leaf Venture Partners, an estimated $3.46M added.
- The largest Protara Therapeutics seller in Q3 2018 was Perceptive Advisors, an estimated $216K sold.
Based on aggregated 13F filings for Q3 2018.